Home  

Random  

Nearby  



Log in  



Settings  



Donate  



About Wikipedia  

Disclaimers  



Wikipedia





Cicletanine





Article  

Talk  



Language  

Watch  

Edit  





Cicletanine is a furopyridine compound usually used in the treatment of hypertension.[1] The drug is most-commonly known as a diuretic drug, but has a broader range of cardiovascular and metabolic activity characterized extensively in the literature (see "Mechanism" below).

Cicletanine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Pharmacokinetic data
Protein binding97.3%
Elimination half-life7.9 h
Identifiers
  • 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol

CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.158.583 Edit this at Wikidata
Chemical and physical data
FormulaC14H12ClNO2
Molar mass261.71 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C3OCc2c3cnc(c2O)C

  • InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3 checkY

  • Key:CVKNDPRBJVBDSS-UHFFFAOYSA-N checkY

  (verify)

Cicletanine was originated and at first marketed by Paris-based Ipsen, who later licensed marketing rights in France to Milan-based Recordati. Ipsen and Recordati both marketed cicletanine under the trade name Tenstaten. The drug is no longer manufactured nor sold by IPSEN; it is currently marketed in France by three generics manufacturers: Viatris, Biogaran, and Teva.

Cicletanine has been shown to be differentially potent in salt-sensitive hypertension.[2]

Mechanism

edit

Cicletanine is officially in the category of “Diurétiques thiazidiques et apparentés” (“thiazide and related diuretics”). Its mechanism of action in hypertension, however, involves decreases in blood pressure (due to vasorelaxant activity) at 50 and 100 mg, doses below the 150 mg that is usually the lowest dose associated with diuretic activity. In fact, a significant majority of cicletanine patients take daily doses of 50 or 100 mg.

While a comprehensive survey of cicletanine's mechanism of action has yet to be published, it is now known that the drug's vasorelaxant activity is due in part to activation of eNOS (endothelial nitric oxide synthase), an enzyme central to endothelial function.

It can inhibit protein kinase C.[3]

References

edit
  1. ^ Sassard J (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
  • ^ Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". Journal of Hypertension. 18 (2): 209–215. doi:10.1097/00004872-200018020-00012. PMID 10694190. S2CID 35374482.
  • ^ Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension. 41 (3): 505–511. doi:10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.
  • edit
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Cicletanine&oldid=1233145909"
     



    Last edited on 7 July 2024, at 14:23  





    Languages

     


    فارسی
    Српски / srpski
    Srpskohrvatski / српскохрватски
    Tiếng Vit
     

    Wikipedia


    This page was last edited on 7 July 2024, at 14:23 (UTC).

    Content is available under CC BY-SA 4.0 unless otherwise noted.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Terms of Use

    Desktop